The path of malaria vaccine development: challenges and perspectives (Q38196455)

30 August 2017

1 reference

title

The path of malaria vaccine development: challenges and perspectives (English)

1 reference

30 August 2017

0 references

1 reference

Marita Troye-Blomberg

series ordinal

2

1 reference

30 August 2017

C Arama

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

Journal of Internal Medicine

30 August 2017

published in

1 reference

30 August 2017

volume

275

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

456-466

1 reference

A large focus of naturally acquired Plasmodium knowlesi infections in human beings

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

21 January 2018

Vaccines against malaria

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Advances and challenges in malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Malaria vaccine development: persistent challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Artemisinin Resistance in Plasmodium falciparum Malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

From vaccines to memory and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Trends in vaccine adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

The selection landscape of malaria parasites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Feeding behaviour and sporozoite ejection by infected Anopheles stephensi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

An estimation of the number of malaria sporozoites ejected by a feeding mosquito

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Plasmodium sporozoites trickle out of the injection site

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Quantitative imaging of Plasmodium transmission from mosquito to mammal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Migration through host cells: the first steps of Plasmodium sporozoites in the mammalian host

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Cell biology and immunology of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Sex and death: the effects of innate immune factors on the sexual reproduction of malaria parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Stress, drugs and the evolution of reproductive restraint in malaria parasites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Malaria transmission-blocking vaccines--how can their development be supported?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Betting on a malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Protection against a malaria challenge by sporozoite inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

The case for a subunit vaccine against malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Progress and challenges for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Malaria vaccine developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Prime-boost vectored malaria vaccines: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Adjuvants for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Molecular vaccines for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

New adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Helping the CD8(+) T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

BCG immunotherapy of bladder cancer: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Combination of adjuvants: the future of vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Combination adjuvants: the next generation of adjuvants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

Specificity of Protective Immunity produced by X-irradiated Plasmodium berghei Sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12223

21 January 2018

Identifiers

DOI

10.1111/JOIM.12223

1 reference

30 August 2017

1 reference